Craig MD - Nu Med Chair Committee

All Insiders . USA . 
Stock . Nu Med Plus . Stakeholders . Insider . Craig MD
NUMD Stock  USD 0.01  0  10.00%   

Insider

Craig MD is Chair Committee of Nu Med Plus
Age 79
Phone801 746 3570
Webhttps://www.nu-medplus.com

Nu Med Management Efficiency

The company has return on total asset (ROA) of (6.6198) % which means that it has lost $6.6198 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (545.2325) %, meaning that it created substantial loss on money invested by shareholders. Nu Med's management efficiency ratios could be used to measure how well Nu Med manages its routine affairs as well as how well it operates its assets and liabilities.
Nu Med Plus currently holds 2.06 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Nu Med Plus has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nu Med until it has trouble settling it off, either with new capital or with free cash flow. So, Nu Med's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nu Med Plus sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for NUMD to invest in growth at high rates of return. When we think about Nu Med's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Susan KimPacific Biosciences of
48
Prof MDBeyond Air
N/A
Erez MeltzerNano X Imaging
67
Roei SamuriInspireMD
N/A
Ross SylviaTandem Diabetes Care
N/A
Paul FlynnDexCom Inc
55
Cenk SumenMaxCyte
50
Kirk HuntsmanVivos Therapeutics
66
James LovgrenMaxCyte
N/A
Marina FelerNano X Imaging
35
Natalie WelchPacific Biosciences of
N/A
Michele CPAPacific Biosciences of
45
Lydia EdwardsNano X Imaging
N/A
Todd HuntsmanVivos Therapeutics
N/A
Stephen TurnerPacific Biosciences of
56
Mark OenePacific Biosciences of
51
Ran DanielNano X Imaging
56
Douglas DoerflerMaxCyte
68
Jonas KorlachPacific Biosciences of
N/A
Edward BargerBeyond Air
N/A
Ran PoliakineNano X Imaging
55
Nu-Med Plus, Inc., a medical device company, engages in the design, development, enhancement, and commercialization of medical devices worldwide. Nu-Med Plus, Inc. was incorporated in 2011 and is headquartered in Salt Lake City, Utah. Nu Med operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 2 people. Nu Med Plus [NUMD] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Return On Equity-545.23
Return On Asset-6.62

Nu Med Plus Management Team

Elected by the shareholders, the Nu Med's board of directors comprises two types of representatives: Nu Med inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NUMD. The board's role is to monitor Nu Med's management team and ensure that shareholders' interests are well served. Nu Med's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nu Med's outside directors are responsible for providing unbiased perspectives on the board's policies.
William Hayde, CEO Pres
Keith Merrell, CFO, Secretary and Treasurer
Craig MD, Chair Committee

NUMD Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Nu Med a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-545.23
Return On Asset-6.62
Current Valuation1.63 M
Shares Outstanding81.35 M
Shares Owned By Insiders61.99 %
Price To Earning19.00 X
Price To Book49.86 X
EBITDA(808.68 K)
Net Income(830.06 K)
Cash And Equivalents2.54 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CCitigroup
GMGeneral Motors
FFord Motor

Other Information on Investing in NUMD OTC Stock

Nu Med financial ratios help investors to determine whether NUMD OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NUMD with respect to the benefits of owning Nu Med security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY